What do clinical trials tell us about what strategies are optimal for RA patients who are inadequate responders to DMARDs and/or biologic therapy?

What do clinical trials tell us about what strategies are optimal for RA patients who are inadequate responders to DMARDs and/or biologic therapy?

What do clinical trials tell us about what strategies are optimal for RA patients who are inadequate responders to DMARDs and/or biologic therapy?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Richard M. Pope, MD

Richard M. Pope, MD

Mabel Green Myers Professor of Medicine
Chief, Division of Rheumatology
Northwestern University Medical School
Chicago, IL